Hangzhou AGS MedTech Co., Ltd. (SHA:688581)
China · Delayed Price · Currency is CNY 53.50
-0.34 (-0.63%)
At close: Aug 14, 2026
Hangzhou AGS MedTech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 587.16 | 588.02 | 632.86 | 506.09 | 368.92 | 305.1 |
Other Revenue | 5.72 | 5.72 | 3.78 | 2.65 | 2.2 | 0.37 |
| 592.88 | 593.74 | 636.63 | 508.75 | 371.11 | 305.47 | |
Revenue Growth | -12.17% | -6.74% | 25.14% | 37.09% | 21.49% | 77.64% |
Cost of Revenue | 169.72 | 173.94 | 180.84 | 149.86 | 119.38 | 108.54 |
Gross Profit | 423.16 | 419.8 | 455.79 | 358.89 | 251.73 | 196.92 |
Selling, General & Admin | 129.07 | 124.4 | 108.89 | 95.38 | 66.59 | 53 |
Research & Development | 76.43 | 75.89 | 59.21 | 41.25 | 31.46 | 24.19 |
Other Operating Expenses | 13.09 | 8.55 | 6.09 | 1.39 | 3.29 | 2.43 |
Operating Expenses | 218.88 | 209.13 | 173.69 | 140.17 | 101.63 | 79.83 |
Operating Income | 204.29 | 210.68 | 282.11 | 218.72 | 150.1 | 117.09 |
Interest Expense | -0.11 | -0.11 | -0.05 | - | - | - |
Interest & Investment Income | 45.2 | 45.76 | 55.23 | 28.91 | 2.59 | 2.52 |
Currency Exchange Gain (Loss) | -6.03 | -6.03 | 0.32 | 0.69 | 11.1 | -4.24 |
Other Non Operating Income (Expenses) | -5.6 | -0.4 | 1.24 | -1.05 | -0.84 | -0.14 |
EBT Excluding Unusual Items | 237.74 | 249.91 | 338.85 | 247.28 | 162.95 | 115.23 |
Gain (Loss) on Sale of Investments | 6.47 | 2.51 | 2.08 | 0.41 | -7.19 | 1.09 |
Gain (Loss) on Sale of Assets | -0.34 | -0.3 | -0.2 | -0.8 | -0.14 | -0.01 |
Asset Writedown | -2.15 | - | - | - | -0 | -0.14 |
Other Unusual Items | 9.93 | 9.93 | 2.87 | 4.78 | 9.94 | 3.79 |
Pretax Income | 251.67 | 262.05 | 343.6 | 251.67 | 165.56 | 119.97 |
Income Tax Expense | 38.5 | 40.61 | 50.21 | 34.43 | 20.6 | 15.17 |
Earnings From Continuing Operations | 213.17 | 221.44 | 293.39 | 217.24 | 144.96 | 104.8 |
Minority Interest in Earnings | 0.64 | 0.28 | - | - | - | - |
Net Income | 213.82 | 221.71 | 293.39 | 217.24 | 144.96 | 104.8 |
Net Income to Common | 213.82 | 221.71 | 293.39 | 217.24 | 144.96 | 104.8 |
Net Income Growth | -27.51% | -24.43% | 35.06% | 49.86% | 38.32% | 131.68% |
Shares Outstanding (Basic) | 80 | 80 | 81 | 73 | 61 | 61 |
Shares Outstanding (Diluted) | 81 | 80 | 81 | 73 | 61 | 61 |
Shares Change | -0.30% | -0.13% | 11.02% | 19.46% | - | - |
EPS (Basic) | 2.66 | 2.76 | 3.64 | 2.99 | 2.39 | 1.72 |
EPS (Diluted) | 2.66 | 2.75 | 3.64 | 2.99 | 2.39 | 1.72 |
EPS Growth | -27.29% | -24.33% | 21.65% | 25.44% | 38.60% | 131.71% |
Free Cash Flow | 148.03 | 87.74 | 266.19 | 169.88 | 96.26 | 102.59 |
Free Cash Flow Per Share | 1.84 | 1.09 | 3.30 | 2.34 | 1.58 | 1.69 |
Dividend Per Share | 1.039 | 1.039 | 1.373 | 1.036 | 0.543 | - |
Dividend Growth | -24.35% | -24.35% | 32.62% | 90.77% | - | - |
Gross Margin | 71.37% | 70.70% | 71.59% | 70.54% | 67.83% | 64.47% |
Operating Margin | 34.46% | 35.48% | 44.31% | 42.99% | 40.45% | 38.33% |
Profit Margin | 36.06% | 37.34% | 46.09% | 42.70% | 39.06% | 34.31% |
Free Cash Flow Margin | 24.97% | 14.78% | 41.81% | 33.39% | 25.94% | 33.59% |
EBITDA | 216.1 | 222.59 | 291.28 | 225.29 | 154.82 | 121.17 |
EBITDA Margin | 36.45% | 37.49% | 45.75% | 44.28% | 41.72% | 39.67% |
D&A For EBITDA | 11.81 | 11.91 | 9.17 | 6.56 | 4.72 | 4.07 |
EBIT | 204.29 | 210.68 | 282.11 | 218.72 | 150.1 | 117.09 |
EBIT Margin | 34.46% | 35.48% | 44.31% | 42.99% | 40.45% | 38.33% |
Effective Tax Rate | 15.30% | 15.50% | 14.61% | 13.68% | 12.44% | 12.64% |
Revenue as Reported | 593.74 | 593.74 | 636.63 | 508.75 | 371.11 | - |